Navigation Links
Researchers discover underlying mechanisms of skin hardening syndromes
Date:5/17/2011

(Boston) - Researchers from Boston University School of Medicine (BUSM) have discovered new details about the underlying mechanisms of skin hardening syndromes. The team connected pharmacological properties of the Novartis Pharma AG drug called balicatib to the skin disorder for the first time after investigating adverse reactions suffered by patients participating in a clinical trial for the treatment of osteoporosis. These findings appear online in the Journal of the American Academy of Dermatology.

Balicatib was developed recently as an osteoporosis drug that can inhibit CathepsinK (catK), an enzyme involved with bone degradation. In a recent trial however, several patients on balicatib experienced hardening of the skin, most frequently around the neck, chest and abdomen. After examining the cases and relating them to recent reports of cathepsin K expression in the skin and the role of cathepsin K in degrading collagen and elastin, the investigators determined that the changes were a direct effect of the drug.

This case study adds a new class of medication to the short list of agents that induce skin hardening syndromes. It also proves that catK affects the skin as well as bones, and marks the first time that skin hardening can be convincingly linked to the pharmacologic properties of a drug.

"This observation emphasizes the importance of intracellular collagen degradation in the skin, a pathway so far vastly underappreciated," said Thomas Ruenger, MD, PhD, a professor and vice-chair of dermatology at BUSM. "This observation also sheds new light on our understanding of the mechanisms involved in morphea, or skin hardening. Failed collagen degradation has so far not been thought to cause morphea."

The researchers believe these findings have far-reaching implications for osteoporosis patients and those suffering from skin hardening syndromes.


'/>"/>

Contact: Nathan Bliss
nathan.bliss@bmc.org
617-638-8490
Boston University Medical Center
Source:Eurekalert

Page: 1

Related medicine news :

1. Researchers map all the fragile sites of the yeast Saccharomyces cerevisiaes genome
2. UH Case Medical Center researchers publish promising findings for advanced cervical cancer
3. Researchers discover new way to kill pediatric brain tumors
4. Researchers Who Discovered First Genes for Stuttering will Present Findings to the National Stuttering Association
5. Researchers create drug to keep tumor growth switched off
6. Urine protein test might help diagnose kidney damage from lupus, UT Southwestern researchers find
7. GUMC researchers say flower power may reduce resistance to breast cancer drug tamoxifen
8. Clemson researchers develop hands-free texting application
9. Researchers find biomarkers in saliva for detection of early-stage pancreatic cancer
10. Researchers chart genomic map spanning over 2 dozen cancers
11. Researchers discover second protective role for tumor-suppressor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2016)... ... May 06, 2016 , ... In honor of Military ... corporate training, and the National Military Family Association, a nonprofit that works to ... second full-tuition scholarship recipient of 2016. , “Being awarded this scholarship by ...
(Date:5/6/2016)... ... , ... “ Crossing Over: Affirmations of Faith in the Midst of the ... those holding vigil to glimpse into the supernatural as their lives ended. With her ... and practically gain insight into providing care to terminal patients. , “I was ...
(Date:5/5/2016)... Tucson, AZ (PRWEB) , ... May 05, 2016 , ... ... more attention being paid to the impact our aging population has on communities and ... help aging adults plan for and face age-related challenges. , Aging Life Care ...
(Date:5/5/2016)... ... 05, 2016 , ... Textile Exchange is excited to announce the ... review. The stakeholder review is an important opportunity for interested parties to give input ... to the wool industry., The RWS is intended to be a global benchmark for ...
(Date:5/5/2016)... ... 05, 2016 , ... Florida Hospital Pepin Heart Institute was ... an alternative to long-term warfarin medication with the newly approved WATCHMAN Left Atrial ... Florida Hospital Pepin Heart Institute doctors successfully implanted the Watchman device in four ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... Israel , May 4, 2016 ... today that BiondVax,s CEO, Dr. Ron Babecoff , will ... New York City . On Thursday, ... Pioneers 2016, a conference presented by Joseph Gunner ... The BiondVax presentation that Dr. Babecoff will be ...
(Date:5/4/2016)... -- Yissum Research Development Company of ... it had signed an exclusive world-wide licensing and research ... protein degradation and immunomodulatory drugs for cancer and immune ... representing first-in-class therapy for hematologic and solid malignancies. Financial ... The novel technology was developed by Yinon Ben-Neriah ...
(Date:5/4/2016)... Valeritas Holdings, Inc. (OTCQB: VLRX) ... offering (APO). This was accomplished via a reverse merger ... a private placement of approximately 5 million shares of ... Under the terms of the reverse merger, which ... will trade on the OTC Markets under the symbol ...
Breaking Medicine Technology: